propranolol has been researched along with Anemia, Sickle Cell in 2 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
Anemia, Sickle Cell: A disease characterized by chronic hemolytic anemia, episodic painful crises, and pathologic involvement of many organs. It is the clinical expression of homozygosity for hemoglobin S.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| De Castro, LM | 1 |
| Zennadi, R | 1 |
| Jonassaint, JC | 1 |
| Batchvarova, M | 1 |
| Telen, MJ | 1 |
| Katz, M | 1 |
| Sokal, MM | 1 |
| Lilling, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Study of Propranolol as Anti-Adhesive Therapy for Sickle Cell Disease[NCT01077921] | Phase 2 | 31 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Sickle Cell Disease (SCD) Biochip': Towards a Simple and Reliable Way to Monitor Sickle Cell Disease[NCT02824471] | 100 participants (Anticipated) | Observational | 2014-10-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Overall change of Diastolic Blood Pressure levels from baseline to post intervention (Week 0 to 6 and week 8 to 14) Placebo vs. Propranolol treated (NCT01077921)
Timeframe: Week 0 to 6 and week 8 to 14
| Intervention | mmHg (Median) |
|---|---|
| Propranolol | 0 |
| Placebo | -1 |
Overall change of Hematocrit (Hct) levels from baseline to post intervention( Week 0 to 6 and week 8 to 14) Placebo vs. Propranolol treated (NCT01077921)
Timeframe: Week 0 to 6 and week 8 to 14
| Intervention | percentage of red blood cells (Median) |
|---|---|
| Propranolol | 1 |
| Placebo | 0 |
Overall change of Hemoglobin (Hgb) levels from baseline to post intervention( Week 0 to 6 and week 8 to 14) Placebo vs. Propranolol treated (NCT01077921)
Timeframe: Week 0 to 6 and week 8 to 14
| Intervention | gm/dL (Median) |
|---|---|
| Propranolol | 0.2 |
| Placebo | -0.1 |
Overall change of LDH levels from baseline to post intervention( Week 0 to 6 and week 8 to 14) Placebo vs. Propranolol treated (NCT01077921)
Timeframe: Week 0 to 6 and week 8 to 14
| Intervention | IU/L (Median) |
|---|---|
| Propranolol | 24 |
| Placebo | -5 |
Overall change of Oxygen Saturation (02Sat) levels from baseline to post intervention( Week 0 to 6 and week 8 to 14) Placebo vs. Propranolol treated (NCT01077921)
Timeframe: Week 0 to 6 and week 8 to 14
| Intervention | percentage of oxygen saturation (Median) |
|---|---|
| Propranolol | 0 |
| Placebo | 0 |
Biomarkers of Endothelial Activation and Dysfunction: Overall change of Plasma levels of sE-selectin measured in triplicate on plasma samples using commercially available ELISA kits from baseline to post intervention ( Week 0 to 6 and week 8 to 14). (NCT01077921)
Timeframe: Week 0 to 6 and week 8 to 14
| Intervention | ng/ml (Mean) |
|---|---|
| Propranolol | -3.9 |
| Placebo | 3.7 |
Biomarkers of Endothelial Activation and Dysfunction: Overall change of Plasma levels of sICAM-1 measured in triplicate on plasma samples using commercially available ELISA kits from baseline to post intervention ( Week 0 to 6 and week 8 to 14) (NCT01077921)
Timeframe: Week 0 to 6 and week 8 to 14
| Intervention | ng/ml (Mean) |
|---|---|
| Propranolol | -6.4 |
| Placebo | 5.4 |
Biomarkers of Endothelial Activation and Dysfunction: Overall change of Plasma levels of sP-selectin measured in triplicate on plasma samples using commercially available ELISA kits from baseline to post intervention ( Week 0 to 6 and weeks 8 to 14). (NCT01077921)
Timeframe: Week 0 to 6 and week 8 to 14
| Intervention | ng/ml (Mean) |
|---|---|
| Propranolol | -5 |
| Placebo | -12.8 |
Biomarkers of Endothelial Activation and Dysfunction: Overall change of Plasma levels of sVCAM-1 measured in triplicate on plasma samples using commercially available ELISA kits from baseline to post intervention ( Week 0 to 6 or week 8 to 14) (NCT01077921)
Timeframe: Week 0 to 6 and week 8 to 14
| Intervention | ng/ml (Mean) |
|---|---|
| Propranolol | -16.7 |
| Placebo | -7.2 |
Overall change of Systolic Blood Pressure levels from baseline to post intervention (Week 0 to 6 and week 8 to 14) Placebo vs. Propranolol treated (NCT01077921)
Timeframe: Week 0 to 6 and week 8 to 14
| Intervention | mmHg (Median) |
|---|---|
| Propranolol | -1.0 |
| Placebo | -1.0 |
The stickiness of SS RBC will be evaluated by a well-established in vitro assay of adhesion of SS RBCs to cultured endothelial cells using a flow chamber. Overall change of adhesion from baseline to post intervention( Week 0 to 6 and week 8 to 14) in unstimulated cells (Sham treated) vs. Stimulated Red Blood Cells (Epi-treated) at 1 dyne/cm2 (NCT01077921)
Timeframe: Week 0 to 6 and week 8 to 14
| Intervention | Percentage of total RBC (Mean) | |
|---|---|---|
| Epinephrine Treated Red blood cells | unstimulated cells (Sham treated) | |
| Placebo | -0.3 | 2.7 |
| Propranolol | 0 | 7.4 |
The stickiness of SS RBC will be evaluated by a well-established in vitro assay of adhesion of SS RBCs to cultured endothelial cells using a flow chamber. Overall change of adhesion from baseline to post intervention( Week 0 to 6 and week 8 to 14) in unstimulated cells (Sham treated) vs. Stimulated Red Blood Cells (Epi-treated) at 2 dyne/cm2 (NCT01077921)
Timeframe: Week 0 to 6 and week 8 to 14
| Intervention | Percentage of total RBC (Mean) | |
|---|---|---|
| Epi-treated Red blood cells | unstimulated cells (Sham treated) | |
| Placebo | -2.8 | 4.4 |
| Propranolol | 0.2 | 2.7 |
The stickiness of SS RBC will be evaluated by a well-established in vitro assay of adhesion of SS RBCs to cultured endothelial cells using a flow chamber. Overall change of adhesion from baseline to post intervention( Week 0 to 6 and week 8 to 14) in unstimulated cells (Sham treated) vs. Stimulated Red Blood Cells (Epi-treated) at 3 dyne/cm2 (NCT01077921)
Timeframe: Week 0 to 6 and week 8 to 14
| Intervention | Percentage of total RBC (Mean) | |
|---|---|---|
| Epi-treated Red blood cells | unstimulated cells (Sham treated) | |
| Placebo | -2.8 | 4.3 |
| Propranolol | 0.5 | -0.1 |
1 trial available for propranolol and Anemia, Sickle Cell
| Article | Year |
|---|---|
Effect of propranolol as antiadhesive therapy in sickle cell disease.
Topics: Administration, Oral; Adult; Anemia, Sickle Cell; Animals; Antisickling Agents; Blood Pressure; Bloo | 2012 |
Effect of propranolol as antiadhesive therapy in sickle cell disease.
Topics: Administration, Oral; Adult; Anemia, Sickle Cell; Animals; Antisickling Agents; Blood Pressure; Bloo | 2012 |
Effect of propranolol as antiadhesive therapy in sickle cell disease.
Topics: Administration, Oral; Adult; Anemia, Sickle Cell; Animals; Antisickling Agents; Blood Pressure; Bloo | 2012 |
Effect of propranolol as antiadhesive therapy in sickle cell disease.
Topics: Administration, Oral; Adult; Anemia, Sickle Cell; Animals; Antisickling Agents; Blood Pressure; Bloo | 2012 |
1 other study available for propranolol and Anemia, Sickle Cell
| Article | Year |
|---|---|
An undeliverable fetus with an ominous fetal heart pattern: an obstetric dilemma.
Topics: Adult; Anemia, Sickle Cell; Cesarean Section; Female; Fetal Diseases; Fetal Heart; Fetal Monitoring; | 1979 |